Get the Stockscreener App
53.35
1.68%
-0.91
Ani Pharmaceuticals Inc stock is traded at $53.35, with a volume of 952.94K.
It is down -1.68% in the last 24 hours and down -3.18% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$54.26
Open:
$53.69
24h Volume:
952.94K
Relative Volume:
3.65
Market Cap:
$1.12B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
-111.15
EPS:
-0.48
Net Cash Flow:
$100.45M
1W Performance:
-5.73%
1M Performance:
-3.18%
6M Performance:
-10.17%
1Y Performance:
+1.95%
1-Day Range:
$53.00
$54.56
1-Week Range:
$52.50
$57.33
52-Week Range:
$52.00
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
53.35 | 1.12B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Wellington Management Group LLP Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
State Street Corp Acquires 58,698 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Insider Sell: Stephen Carey Sells 7,500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus.com
Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock By Investing.com - Investing.com South Africa
Ani Pharmaceuticals CFO sells $418,425 in stock - Investing.com
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares - Simply Wall St
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Barclays PLC - MarketBeat
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock - Investing.com
Ani Pharmaceuticals Sr. VP Meredith Cook sells $14,060 in stock By Investing.com - Investing.com Australia
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.03 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Key Pharmaceutical Suspension Market Trend 2024-2033: ANI Pharmaceuticals Launches Kionex Suspension - EIN News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decrease in Short Interest - MarketBeat
Insider Sell: Krista Davis Sells 1,000 Shares of ANI Pharmaceuti - GuruFocus.com
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of ANI Pharmaceuticals (ANIP) with Outperform Recommendation - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Leerink Partners - MarketBeat
Where ANI Pharmaceuticals Stands With Analysts - Benzinga
Charles Schwab Investment Management Inc. Buys 8,869 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Hotchkis & Wiley Capital Management LLC Buys Shares of 52,080 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Intrauterine Devices Market Report Forecasts and Company - GlobeNewswire
Intrauterine Devices Market Report Forecasts and Company Analysis 2024-2032, Profiles of AbbVie, Bayer, Teva Pharmaceuticals, ANI Pharmaceuticals, Mylan, CooperSurgical. and DKT International - Yahoo Finance
Ani Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Martingale Asset Management L P Purchases 13,719 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Bank of Montreal Can Makes New $13.04 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Down 2.9%Here's Why - MarketBeat
Intech Investment Management LLC Acquires New Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Ani Pharmaceuticals Insider Sold Shares Worth $1,941,442, According to a Recent SEC Filing - Marketscreener.com
Ani Pharmaceuticals CEO Nikhil Lalwani sells $1.94 million in stock - Investing.com India
Ani Pharmaceuticals CEO Nikhil Lalwani sells $1.94 million in stock By Investing.com - Investing.com Australia
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Holdings Decreased by Rubric Capital Management LP - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Eagle Asset Management Inc. Purchases New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals CEO to Present at Piper Sandler Healthcare Conference - StockTitan
Pacer Advisors Inc. Acquires 565,910 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Thompson Siegel & Walmsley LLC Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Global Alpha Capital Management Ltd. - MarketBeat
Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St
ANI Pharmaceuticals Q3 2024 Earnings Preview - MSN
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update - MarketBeat
Mizuho Markets Americas LLC Makes New $11.67 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Athlete′s Foot Drugs Market: Global Trends, Demand, - openPR
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance
Rubric Capital Management LP Adjusts Stake in ANI Pharmaceuticals Inc - GuruFocus.com
ANI Pharmaceuticals Inc (ANIP) Stock Price Up 2.37% on Nov 13 - GuruFocus.com
Lisanti Capital Growth LLC Has $890,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals maintains Buy rating, target at $94 By Investing.com - Investing.com UK
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):